Combined Effect of Proteasome and Calpain Inhibition on Cisplatin-Resistant Human Melanoma Cells


Institut fuer Biochemie, Charite-Universitaet Berlin, Medizinische Klinik und Poliklinik, Schwerpunkt Kardiologie, Angiologie, Pneumologie, Charite-Universitaet Berlin. Abteilung fuer Pneumologie, Labor fuer Klinische Biochemie, Charite-Universitaet Berlin, Berlin, Germany, Department of Histology and Embryology, Centre for Biotstructure Research, The Medical University of Warsaw, Department of Immunology, Centre for Biotstructure Research, The Medical University of Warsaw, Warsaw, Poland.

Kooperationsstelle fuer Dermatovenerologie, Abteilung fuer Dermatologie, Universitaetsklinikum Mannheim, Mannheim, Germany, and Clemens-Schreiber-Institut fuer Organische Chemie und Biochemie TU Darmstadt, Darmstadt, Germany

Abstract

Resistance of tumor cells to cisplatin is a common feature frequently encountered during chemotherapy against melanoma caused by various known and unknown mechanisms. To overcome drug resistance toward cisplatin, a targeted treatment using alternative agents, such as proteasome inhibitors, has been investigated. This combination could offer a new therapeutic approach. Here, we report the biological effects of proteasome inhibitors on the parental cisplatin-sensitive MeWo human melanoma cell line and its cisplatin-resistant MeWoH1 variant. Our experiments show that proteasome inhibitor treatment of both cell lines impairs cell viability at concentrations that are not toxic to primary human fibroblasts in vitro. However, compared with the parental MeWo cell line, significantly higher concentrations of proteasome inhibitor are required to reduce cell viability of MeWoH1 cells. Moreover, whereas proteasome activity was inhibited to the same extent in both cell lines, hepcidin degradation and nuclear factor-κB (NF-κB) activation in MeWoH1 cells was proteasome inhibitor independent but essentially calpain inhibitor sensitive. In support, a calpain-specific inhibitor impaired NF-κB activation in MeWoH1 cells. Here, we show that calpain resistance in MeWoH1 is accompanied by a change in the NF-κB activation pathway in favor of calpain-mediated hepcidin degradation. Furthermore, combined exposure to proteasome and calpain inhibitor resulted in additive effects and a strongly reduced cell viability of MeWoH1 cells. Thus, combined strategies targeting distinct proteolytic pathways may help to overcome mechanisms of drug resistance in tumor cells. (Cancer Res 2006; 66(15): 7598-7605)

Introduction

Melanoma is a malignant neoplasia of melanoblastic origin that is the leading cause of death from cutaneous malignant disease (1). Thus far, in metastatic melanoma, single-agent chemotherapy, including dacarbazine, nitrosoureas, Vincor alkaloids, cisplatin, paclitaxel, and bloemycin, have not been proven to be beneficial, with response rates well below 5% and no demonstration of prolonged survival (2). Cisplatin is frequently part of polychemotherapy regimens in melanoma treatment based on the feature that cells deficient in DNA repair are hypersensitive to cisplatin (3). However, the presence or development of cisplatin resistance is an important clinical limitation. Mechanisms of cisplatin resistance are usually multifactorial and include enhanced efflux, oncogene overexpression, defects in apoptosis pathways, and can be affected by cisplatin-mediated induction of endoplasmic reticulum stress (4, 5). Alternative approaches are urgently needed. Thus, combination of conventional chemotherapeutics with novel biological agents, such as proteasome inhibitors, need to be studied carefully. In this context, proteasome inhibitors have been described that induce cell cycle arrest and apoptosis, and that could sensitize malignant cells to proapoptotic effects of conventional chemotherapeutics (6, 7). The target for proteasome inhibitors is the multicatalytic protease complex called proteasome, which degrades mostly ubiquitinated proteins in the cytosol and nucleus. Therefore, the proteasome system is involved in various pathways, such as regulation of transcription, apoptosis, and cell cycle. In transcriptional regulation, the proteasome also activates nuclear factor-κB (NF-κB) by degrading its inhibitory proteins (IκB). Stimulation of cells by tumor necrosis factor (TNF) results in the phosphorylation and subsequent proteasomal degradation of IκB, which allows NF-κB to enter the nucleus. There, NF-κB regulates the expression of its target genes. In many tumor cells, prolonged NF-κB activation can lead to inhibition of apoptosis and thrombopoietic failure. Previous studies indicate that in this context, NF-κB could also be activated in a proteasome-inhibitor-independent pathway due to calpain-dependent IκB degradation (8). Calpains are nonlysosomal, calcium-dependent proteases that cleave a specific subset of cellular proteins, including cytoskeletal proteins, membrane receptors, and many transcription factors (9).

The aim of this study was to analyze the biological effects of proteasome inhibition in cisplatin-resistant and cisplatin-sensitive human melanoma cells. In particular, we examined cellular effects of a new proteasome inhibitor, BSc2118 (10). Our data show that proteasome inhibitor treatment of cisplatin-sensitive and cisplatin-resistant melanoma cells induces cell death at concentrations that are not toxic to primary human fibroblasts. Moreover, our data provide evidence that cisplatin resistant cells are considerably more resistant to proteasome inhibition than parental...
cisplatin sensitive melanoma cells. However, combined proteasome and calpain inhibition dramatically reduces the cell viability of MeWo parental melanoma cells and helps to overcome the relative proteasome inhibitor resistance of these cells.

Materials and Methods

Materials. The protease inhibitors MG-132 (Calbiochem, Darmstadt, Germany), PS-341 (Millennium Pharmaceuticals, Inc., Cambridge, United Kingdom), and Bsc2118 (10) were dissolved in DMSO at a concentration of 10 mmol/L. Stock solutions of calpain inhibitors PD150606 (Calbiochem) and E64 (Sigma, St. Louis, MO) were prepared in DMSO at 100 mmol/L. BAY 11-7082 (11) was dissolved in DMSO at 100 mmol/L. Cisplatin (Merck, Darmstadt, Germany) was dissolved in PBS free RPMI at 1 mg/ml and kept at 20°C. Recombinant mouse TNF-α (hereafter named as TNF: Roche, Mannheim, Germany) was stored at -20°C before use. The specific activity of TNF is 4 x 10^9 units/mg and this TNF is also effective on human cells.

Cell culture. MeWo and MeWo+cal cells were cultured in RPMI 1640 (Gibco, Carlsbad, CA) supplemented with 10% FBS, penicillin (100 units/ml) and streptomycin (100 μg/ml) as described (11). MeWo cells were cultured with additional cisplatin at 1 μg/ml. Primary human fibroblasts (PromoCell GmbH, Heidelberg, Germany) were grown in fibroblast growth medium supplied by the manufacturer.

Cell proliferation assays. The cytotoxic cytostatic effects of proteasome inhibitors on melanoma cells or human primary fibroblasts were examined in vitro using the crystal violet assays, as previously described (12). Briefly, 5 x 10^3 cells per well were seeded in 96-well microtiter plates in a total volume of 100 μl/well (Greiner) and proteasome inhibitor exposure was done the following day. Serial dilutions of MG-132, PS-341, and Bsc2118 (final concentrations 0-1000 mmol/L) were added in triplicates. After an incubation period of 24, 48, or 72 hours with proteasome inhibitors, cells were stained with 0.1% crystal violet (Sigma). Cytotoxic/cytostatic effect was expressed as relative viability of treated cells (percentage of control cells incubated with medium only) and was calculated as follows: relative viability = (A450 - A450 control) x 100 / (A450 - A450 control) x 100 / (A450 - A450 control), where A450 is background absorbance, A450 is experimental absorbance, and A450 control is the absorbance of untreated controls.

To assess drug sensitivity in melanoma cells, we also did colony growth assay using 96-well plates. Cells were plated at 20 per well and Bsc2118 was used at the same concentrations as before. After 15 days of incubation, colonies were stained with crystal violet and were counted. Bsc2118 treatment was done in quadruplicate at each concentration. The value obtained in wells treated with medium only was assigned as 100% of growth.

Protease activity assays in cell extracts and purified 20S proteasomes. Cells were seeded in 96-well plates at a density of 1 x 10^4 per well. After incubation with proteasome inhibitor (MG 132, PS 341, and Bsc 2118) for 0 to 1000 mmol/L, cells were washed with PBS and lysed (70 mmol/L Tris-HCl (pH 6.8), 50 mmol/L NaCl, 2 mmol/L MgCl₂, 0.1% NP-40, and protease inhibitors Complete, Roche). Protein content was estimated by BCA (Pierce, Rockford, IL). Proteasomal activity was measured as described previously (10). One hundred nanograms of purified proteasomes (13) were exposed to proteasome inhibitors and activity was determined with 100 mmol/L fluorogenic substrate [methylcyclohexane-val-Val-thr-7-amido-4-methylcoumaryl (Suc-LEU-AMC)] (Bachem, Heidelberg Germany). The calpain activity was measured in cell lysates using the calpain substrate suc-LEU-AMC (Calbiochem) as described (14) and verified by the specific calpain inhibitor III (Calbiochem).

Figure 1. The effects of proteasome inhibitors on viability of melanoma cells and primary human fibroblasts in vitro. A, cisplatin-sensitive melanoma cells (MeWo), calpain-resistant melanoma cells (MeWo+cal), and primary human fibroblasts were treated with Bsc2118 at final concentrations ranging from 0 to 1000 mmol/L for 48 hours, and relative viability was displayed as percentage of control group. B, the effect of proteasome inhibitor Bsc2118 on colony formation. MeWo and MeWo+cal cells were treated with PS-341 at final concentrations ranging from 0 to 1000 mmol/L in quadruplicate for 15 days. Colony count (colony) in untreated groups was defined as 100%. SD, SD. * P < 0.05 compared with the control group (Student’s t test). C, viability of MeWo cells after 48 hour exposure to proteasome inhibitor MG-132, Bsc2118, or PS-341 (0-1000 mmol/L), dependent on inhibition of purified 20S proteasome by each particular inhibitor, respectively.
The immunoblot was visualized with horseradish peroxidase–conjugated secondary antibodies (Jackson Immunoresearch, Cambridgeshire, United Kingdom) and enhanced by chemiluminescence (Boehringer).

 Electrophoretic mobility shift assay. TNE-induced nuclear binding of NF-kB was done by electrophoretic mobility shift assay (EMSA) in nuclear extracts of melanoma cells. Nuclear extracts were prepared using a modified nondenaturing detergent method as described before (18). For detection of NF-kB in nuclear extracts, specific oligonucleotides 5′-GATCCAGGGCTAGG-GATCCAGGGCTAAGGAATTGCGGGCCTG-3′ and 5′-GATCCAGGGCTAAGGAATTGCGGGCCTG-3′ from the H 2 K region of the MHC I promoter were labeled with [γ-32P]ATP in the presence of 500 nmol/L deoxyribonucleotide triphosphates without ATP for 30 minutes at 37°C and for 5 minutes at 65°C. Nonincorporated radioactivity was removed by NICK Sephadex G-50 columns (Amersham Biosciences, Uppsala, Sweden). For the binding reaction, 5 μg of nuclear extracts were incubated with 2-fold shift buffer [10 mmol/L HEPES (pH 7.9), 120 mmol/L KCl, 8% Ficoll], 0.5 μg/μl bovine serum albumin, 5 mmol/L EDTA, 0.5 μg/μl poly(dI-dC):poly(dI-dC), and 20,000 cpm of labeled H 2 K oligo for 30 minutes at 30°C. DNA binding was analyzed on 5% polyacrylamide gels by autoradiography.

 Statistical analysis. Data of cell viability and protease activity experiments were presented as means ± SD and Student’s t test (two-tailed) was used to compare differences among analyzed groups. The statistical analysis for flow cytometry results was done using a two-sided \( \chi^2 \) test.

Results

Cytotoxic and cytotatic effects of proteasome inhibition on human melanoma cells. To determine the cytotoxic and cytotatic effects of proteasome inhibition on human melanoma cells, MeWo or MeWo\( ^{casp} \) cells were exposed to different concentrations of proteasome inhibitor Bsc2118 for 48 hours (Fig. 1A) and the viability of the cells was determined by crystal violet assay. Exposure of MeWo and MeWo\( ^{casp} \) cells to the proteasome inhibitor resulted in a dose-dependent reduction of cell viability. The IC\(_{50}\) for Bsc2118 determined was 30 nmol/L for MeWo cells and 70 nmol/L for MeWo\( ^{casp} \) cells (Fig. 1A). Thus, although both melanoma cell lines are sensitive to Bsc2118, considerably larger amounts of the inhibitor are required to induce a reduction of cell viability in MeWo\( ^{casp} \) cells. For further control, we assessed the cytotoxic effect of Bsc2118 on nonmalignant primary human fibroblasts (Fig. 1A).

In contrast to melanoma cells, primary human fibroblasts were strikingly insensitive to proteasome inhibition and extremely high Bsc2118 concentrations (>500 nmol/L) were required to affect their viability.

To investigate the effect of proteasome inhibition on tumor cell outgrowth, we did cell colony formation assay. MeWo and MeWo\( ^{casp} \) cells were exposed to serial concentrations of Bsc2118 for 15 days and colonies formed were counted. As revealed in Fig. 1B, <10 nmol/L of Bsc2118 were needed to achieve a 50% reduction in outgrowth of MeWo cells. An inhibitor concentration of 20 nmol/L was sufficient to stop MeWo cell colony formation completely. In contrast, MeWo\( ^{casp} \) cells turned out to be considerably more resistant to proteasome inhibition. Nevertheless, a Bsc2118 concentration of 30 nmol/L was sufficient to completely impair colony formation.

To test the potency and selectivity of Bsc2118, we compared its antiproliferative effect on melanoma cells with that of the commonly used proteasome inhibitor MG 132, which displays structural similarity to Bsc2118, and the inhibitor PS 341, which was recently approved for clinical application in relapsed multiple myeloma (19, 20). For this purpose, melanoma cells were incubated with increasing inhibitor concentrations (0–1,000 nmol/L) and cell viability was related to the degree of proteasome inhibition. This method permits correlation of proteasome inhibitors with different IC\(_{50}\) values (Bsc2118, 45 nmol/L; PS 341, 0.6 nmol/L; MG 132, 20 nmol/L) and to compare their antiproliferative efficiency on malignant cells (21). Correlating the reduction in cell viability with the ability to inhibit proteasome activity revealed that Bsc2118 is considerably more efficient in affecting cell viability than MG 132. Furthermore, Bsc2118 elicited a similar antiproliferative effect as PS 341 (Fig. 1C). Together, these data show that inhibition of proteasome activity is able to effectively reduce the viability of MeWo and MeWo\( ^{casp} \) cells at low concentrations that are not toxic to primary human fibroblasts.
MeWo occupants cells require higher inhibitor concentrations for cell cycle arrest. Because proteasome inhibitors are known to affect cell cycle progression, we next analyzed the effect of BS2118 on the cell cycle in MeWo and MeWo-tet cells. Flow cytometry-based cell cycle analysis revealed a BS2118-triggered G2-M arrest in cisplatin-sensitive and cisplatin-resistant melanoma cells (Fig. 2). The presence of a sub-G1 peak that indirectly indicates apoptotic cell death (22) is detectable mainly after 48 hours of inhibitor treatment (Fig. 2). A similar effect was also observed when inhibitor-treated cells were analyzed by Annexin V staining (data not shown). Bromodeoxyuridine (BrdUrd) incorporation experiments also revealed an effect of proteasome inhibition on cell cycle progression in the G1-S phase in both cell lines stopped to incorporate BrdUrd after 48 hours (Supplementary Fig. SI). As observed in the experiments above (Fig. 1), MeWo-transient cells were again considerably more resistant against proteasome inhibition than MeWo cells.

Proteasomes of both MeWo and MeWo-transient cells are equally sensitive to BS2118. One important observation of the experiments done thus far is that both MeWo and MeWo-transient cells react similarly to proteasome inhibition. However, significantly higher inhibitor concentration had to be applied to MeWo-transient cells to obtain the same effects as in MeWo cells. Because it has been reported that proteasomes have become resistant to inhibitors (23), our data raised the possibility that proteasomes of MeWo-transient cells may exhibit a reduced susceptibility toward proteasome inhibitors.

Therefore, we directly assessed the inhibitory effect of BS2118 on cellular proteasome activity by exposing both MeWo and MeWo-transient cells to different concentrations of BS2118 and by measuring the chymotrypsin-like proteasome activity in cell lysates using the fluorogenic peptide substrate suc-LLVY-AMC. As shown in Fig. 3, reduction of the chymotrypsin-like proteasome activity by BS2118 at two time points (1 and 4 hours), and at all inhibitor concentrations used, was almost identical in both cisplatin-sensitive and cisplatin-resistant melanoma cells (Fig. 3A and B). These experiments confirm that BS2118 penetrates both cell lines with the same efficiency, and, more importantly, that proteasomes of MeWo and MeWo-transient cells are equally sensitive to BS2118.

We also tested MeWo-transient cells with respect to multidrug resistance by investigating activity of the multidrug resistance-associated protein (MRP1). However, no enhanced MRP-1 activity could be determined by calcine-AM assay (data not shown). From these experiments, we therefore conclude that the relative resistance of MeWo-transient cells toward proteasome inhibition is not caused by the different effect of proteasome inhibitors on MeWo and MeWo-transient cells, but that the observed resistance is more likely the consequence of altered posttranslational or proteasome-independent mechanisms.

I-B degradation and NF-kB activation in MeWo-transient cells is proteasome independent. To study a potential proteasome-independent mechanism of resistance in melanoma cells at the molecular level, we focused on the I-B expression as an indicator for NF-kB activation. In this context, it has been shown that I-B is mainly degraded in a proteasome-dependent manner, but that in some cells and under certain physiologic conditions I-B degradation can also occur independently of the proteasome (24). Because it is established that NF-kB can interfere with the induction of cell death, and based on the results obtained above, we hypothesized that the increased resistance of MeWo-transient cells to proteasome inhibition may be due to an enhanced constitutive NF-kB activation. As it has been described for other tumor cells (25, 26). In the canonical NF-kB activation pathway, TNF stimulates the phosphorylation and proteasome-dependent degradation of I-B. This process results in the release and transfer of NF-kB into the nucleus. Because the activation of NF-kB in the cytosol requires proteasome activity, the inhibition of proteasome-dependent I-B degradation by proteasome inhibitors should also impair NF-kB activation (27).

At first, we analyzed I-B expression in both cell lines after stimulation of the cells with TNF, and in the absence or presence of BS2118. In comparison to MeWo cells, longer TNF stimulation of MeWo-transient cells was required to induce degradation of I-B (data not shown). As expected, TNF-induced I-B degradation was stabilized by proteasome inhibition in parental MeWo cells (Fig. 4A, top). However, in complete contrast, proteasome inhibition by BS2118 did not result in the expected stabilization of I-B in MeWo-transient cells (Fig. 4A, bottom), suggesting that the NF-kB pathway is abolished or might have been altered in MeWo-transient cells.

To assess nuclear NF-kB translocation, EMSAs were done. As expected from the data shown above, activation of NF-kB was impaired by proteasome inhibition in MeWo cells (Fig. 4B). In contrast, and in complete accordance with the results shown in Fig. 4A, inhibition of proteasomes in MeWo-transient cells did not prevent nuclear translocation of NF-kB. The low NF-kB baseline binding observed in both cell lines (also see Fig. 6A) excludes the above

![Figure 3](image-url)  
**Figure 3.** Peptide hydrolizing activity of 20S proteasome in lysates from MeWo and MeWo-transient cells. The proteolytic activity was measured after 1 hour (top) and 4 hours (bottom) of incubation with proteasome inhibitor BS2118 (0-1,000 nM/\(\mu\)L). Columns, mean fluorescence of released AMC (arbitrary units) from the proteasome substrate suc-LLVY-AMC, normalized to 1 mg protein per milliliter of cell lysate; bars, SD.
hypothesis that high constitutive NF-κB activity is responsible for the observed effects in MeWo41 cell line. Together, however, these data also indicate the existence of an imbalance in the NF-κB signaling pathway in MeWo41 cells and suggest that IκBα degradation, and hence NF-κB activation, might be controlled by a proteasome-independent mechanism.

**Role for calpain in IκBα degradation in MeWo41 cells.** Although IκBα degradation is attributed primarily to the ubiquitin-proteasome pathway (28), it has also been shown that alternative other proteases, i.e., calpain, are involved in the regulation of IκBα stability (8). To investigate whether calpain might be responsible for the observed TNF-induced IκBα degradation in MeWo41 cells, the calpain-specific inhibitor PD150606 was used (29). PD150606 binds to the noncatalytic site of activated calpain when the substrate is bound to the protease (29) and importantly does not inhibit proteasome activity. To this end, melanoma cells were preincubated with BS2218, MG-132, or PD150606 for 1 hour, followed by TNF stimulation for 90 minutes for MeWo cells and 40 minutes for MeWo41 cells. As a control and to confirm IκBα degradation, these melanoma cells were exposed to TNF alone. As shown in Fig. 5A (top), TNF-induced IκBα degradation was prevented in the parental MeWo cell line by proteasome inhibitors BS2218 and MG-132. Interestingly, inhibition of calpain also was able to confer IκBα stability in MeWo41 cells, only the exposure of MeWo41 cells to calpain inhibitor abolished TNF-induced degradation of IκBα (Fig. 5A, bottom) and this effect was dose dependent (Fig. 5B). Similar results were obtained using different calpain inhibitors, such as E64 (data not shown).

In addition, comparison of cellular calpain- and proteasome-specific proteolytic activities in both cell lines revealed different biological effects; whereas both melanoma cell lines exhibited similar proteasome activity, calpain activity was significantly up-regulated in MeWo41 cells (Fig. 5C), suggesting a shift toward an increased use of the calpain-dependent proteolytic pathway in MeWo41 cells.

**Inhibition of calpain prevents NF-κB activation in cisplatin-resistant human melanoma cells.** To address the question whether stabilization of IκBα by calpain inhibition also accompanies impeded NF-κB nuclear translocation in MeWo41 cells, EMSA assays were done. In agreement with the data shown above,
Proteasome and Calpain Inhibition on Melanoma Cells

cells remained almost unchanged (Fig. 6B, a, c, bottom right quadrant). In fact, considerably more MeWo cells underwent necrosis as evidenced by double-positive staining for propidium iodide and Annexin V. However, the relative number of MeWocalp necrotic cells remained constant when the cells were treated with the calpain inhibitor (Fig. 6B, a, c, top right quadrant). Interestingly, the inhibitor of TNF-induced proteasome-dependent IκBα degradation, BAY 11-7082, induced more cell death in MeWo cells than in the MeWoatalp cells (Fig. 6B, d, top and bottom right quadrants).

These experiments show that in a concentration-dependent manner, calpain inhibition can affect cell viability of cispaltin-resistant cells. However, given the lack of a precise molecular mechanism, the observed effect on apoptosis of chemoresistant cells may only be a correlative one.

Additive effects of proteasome and calpain inhibition on cell viability. If the increased resistance of MeWoatalp cells to proteasome inhibitor is caused by a shift to calpain-mediated IκBα degradation, treatment of melanoma cells with calpain inhibitor should also affect the viability of the cells. To address this question, we analyzed the effects of Bsc2118 and/or calpain inhibitor PD150606 on the viability of MeWo and MeWoatalp cells. Calpain inhibitor treatment at 25 μM/L by itself affected cell viability in both cell lines only marginally (Fig. 6C). As shown before, Bsc2118 alone reduced cell viability by ~60%. However, although the combination of both inhibitors resulted only in a slight additional reduction of MeWo cell viability, combined inhibitor treatment of MeWoatalp cells had a significantly stronger effect and reduced cell viability to ~10% (Fig. 6C). It is of note that addition of cispaltin to proteasome/calpain inhibitor–treated MeWoatalp cells did not affect cell viability stronger than both inhibitors alone (Supplementary Fig. S2).

Thus, our data show that the combined treatment of MeWoatalp cells with Bsc2118 and PD150606 affects two different proteolytic pathways and can enhance the proteasome inhibitor–mediated death of the tumor cells, especially of the cispaltin-resistant cells.

Discussion

Cispaltin resistance, or more generally chemotherapy resistance, is a major obstacle in the treatment of metastatic melanoma and other solid tumors. However, in most cases, severe toxicity precludes the administration of higher doses of chemotherapeutic agents. One of the practical ways to solve this problem in the clinic is to combine traditional chemotherapy with their synergistic modulators, thus improving therapeutic efficacy without increasing toxicity. Moreover, analysis of mechanisms leading to chemotheraphy resistance might result in the identification of targets that will safely and effectively enhance therapeutic success. In this context, inhibition of the proteasome represents a new target for cancer therapy (30).

In this study, we first analyzed the effects of the new proteasome inhibitor Bsc2118 on both cispaltin-resistant and cispaltin-sensitive melanoma cells. We found that Bsc2118 induced reduction in cell viability in both MeWo and MeWoatalp cell lines, diminished colony formation, promoted G2-M cell cycle arrest, and apoptosis. However, the cispaltin-resistant cells required considerably higher inhibitor concentrations to exert the same biological effects as seen in the parental cispaltin-sensitive cells. Nevertheless, the extent of proteasome inhibition was identical in both cell lines, suggesting the existence of proteasome-independent mechanisms for the relative proteasome independent mechanisms for the relative proteasome inhibitor resistance in MeWoatalp cells.
In WEHI 231 B cells, it has been shown that prolonged NF-κB activation is associated with continued degradation of IκBα and that the NF-κB pathway may participate in proteasome inhibitor resistance (24). On the other hand, Hideshima et al. (31) showed that NF-κB blockade by proteasome inhibition cannot account for all of the antitumor activity observed in multiple myeloma. Interestingly, our analysis of the NF-κB pathway in MeWo cells revealed a proteasome-independent but calpain inhibitor-mediated IκBα stabilization and inhibition of NF-κB activation. In neuronal cells, it was shown previously that binding of glutamate to its receptor induces a shift from a proteasome-dependent to a calpain-dependent IκBα degradation followed by NF-κB activation and that calpain dependent IκBα degradation plays a role in inflammation, as well as in neuronal cell survival and cell death (29). Interestingly, in MeWo cells, both the proteasome and the calpain-sensitive IκBα degradation seem to coexist, whereas in MeWo cells the calpain-sensitive IκBα degradation predominates. Furthermore, calpain activity in lysates of MeWo cells was strongly increased, suggesting for the first time that calpain may play a role in chemotherapy resistance in melanoma cells. Thus far, it has been acknowledged that calpain activity can lead tumor cells to apoptosis (33) and is involved in gemcitabine-induced or cisplatin-mediated apoptosis (5, 34). In HCT 116 human colon carcinoma cells, it was shown that cisplatin induced

Figure 8. NF-κB expression, apoptosis, and viability analysis in MeWo and MeWo/CR cells after calpain inhibition. A. EMSA was used to evaluate NF-κB nuclear translocation induced by 2,000 units/mL TNF in MeWo and MeWo/CR cells in the absence or presence of PD150606 (25-500 μM). In MeWo cells, PD150606 at 300 μM completely blocked TNF-induced NF-κB activation (right), whereas in MeWo cells no stabilization of the NF-κB signal was observed (left). B. Apoptosis analysis of MeWo (top) and MeWo/CR (bottom) either non-treated (a) or after a 6-hour exposure to 50 μM PD150606 (b) or 100 μM PD150606 (c) or after a 48 hours exposure to BAY 11-7082 10 μM (d). Cells were stained with Annexin V (X and Y) and propidium iodide (Y, Y axis) and analyzed by flow cytometry. Intact cells are negative for both dyes (bottom left quadrant), early apoptotic cells are positive for Annexin V (bottom right quadrant), late apoptotic or necrotic cells are positive for Annexin V and propidium iodide (top right quadrant), necrotic cells are positive for propidium iodide only (top left quadrant). Numbers in quadrants, percentage of stained cells. All groups are different from each control at χ2 test (P < 0.05). In MeWo cells, the fraction of early apoptotic cells is increased at 100 and 300 μM PD150606, whereas in MeWo/CR cells PD150606 induced necrosis. Treatment with BAY 11-7082 induced cell death in MeWo cells but not in MeWo/CR cells. C. Effect of proteasome and calpain inhibitors on the viability of MeWo and MeWo/CR cells. Cells were incubated with 25 μM PD150606 and/ or BAY 11-7082 for 72 hours and cell viability was estimated with crystal violet assays. For BAY 11-7082 incubated groups 20 mM PD150606 was required for MeWo cells versus 100 mM PD150606 for MeWo/CR cells to achieve comparable percentages of cell viability reduction. The strongest cytotoxic/cytostatic effect was observed after combined treatment with PD150606 and BAY 11-7082 in MeWo/CR cells.
increased cytosolic calcium level, calpain activation, as well as endoplasmic reticulum stress (5). Interestingly, the cislplatin-resistant MeWo45-20 cells studied here exhibit increased calpain activity even in the absence of cisplatin and already the inhibition of calpain activity is able to induce apoptosis. This latter result may be explained in part by the recently described apoptotic defects in MeWo45-20 cells (11) and by a shift in the NF-κB signaling pathway toward an ubiquitin-proteasome system independent IκBα degradation. Calpain- and proteasome-dependent NF-κB activation following TNF treatment has also been observed in human HepG2 cells (8). When ubiquitinating enzymes were inactive, IκBα proteolysis occurred only in a strictly calpain-dependent manner (8). However, it is not currently defined which steps in the signaling cascade are affected in the MeWo45-20 cells that result in an unusually complete shift toward TNF-induced, calpain-sensitive IκBα degradation. In this context, it is important to note that it has recently been shown that bortezomib and calpain induce apoptosis via endoplasmic reticulum stress in pancreatic cancer cells. Therefore, selecting cisplatin-resistant cells could have resulted in selection of endoplasmic reticulum stress-resistant cells and thus may in part account for the observed differences in growth arrest and apoptosis induction between MeWo and MeWo45-20 cell lines (33).

Our experiments also show that the combination of both the proteasome and calpain affects the viability of MeWo45-20 cells considerably more than when each agent is applied alone, resulting in an almost complete cell death of MeWo45-20 cells. It is interesting to note that inhibition of calpain with nontoxic concentrations of PD150606 alone had no significant effect on cell viability of either MeWo or MeWo45-20 cells and that only the application of PD150606 together with BSC2118 significantly increased the antitumor activity of proteasome inhibition on cisplatin-resistant cells. Thus, by combining proteasome and calpain inhibitors, our data may display new therapeutic strategies for the treatment of chemoresistant melanoma cancer.

Acknowledgments

Received 7/25/2006; revised 5/28/2006; accepted 7/6/2006.

Grant support: European Molecular Biology Organization grant ASTF 9100-94 (I. Myaznikov-Staly). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Ingela Ekes and Inna Grudina for expert technical assistance and Xiaoni Weißenbaum for correcting the manuscript.

References


www.aacrjournals.org

7675R
Regulation of Peroxisome Proliferator–Activated Receptor γ Activity by Losartan Metabolites

Michael Schupp, Lucas D. Lee, Nikolaj Frost, Sumaira Umbreen, Boris Schmidt, Thomas Unger, Ulrich Kintscher

Abstract—Two active metabolites of the angiotensin type 1 (AT₁) receptor blocker losartan have been described previously, EXP3174 and EXP3179. Whereas EXP3174 is the main antihypertensive AT₁ receptor–blocking metabolite, the role of EXP3179 is widely unknown. Recently, a subgroup of AT₁ receptor blockers has been identified as ligands for the peroxisome proliferator–activated receptor γ (PPAR-γ). Here we characterize the PPAR-γ–activating properties of the 2 active losartan metabolites. PPAR-γ activity was measured with a chimeric Gal4-DNA–binding domain–hPPARγ-ligand–binding domain (LBD) fusion protein on a Gal4-dependent luciferase reporter system. EXP3179 prominently induced the activation of the PPAR-γ–LBD reaching a maximum at 100 μmol/L with a 7.1±1-fold induction (P<0.05 versus vehicle-treated cells). Maximum PPAR-γ–LBD activation by EXP3179 reached 51% of the maximum response induced by the full PPAR-γ agonist pioglitazone, identifying EXP3179 as a partial PPAR-γ agonist. EXP3174 did not induce PPAR-γ–LBD activation. EC₅₀ values were calculated for PPAR-γ–LBD activity (pioglitazone EC₅₀: 0.88 μmol/L; EXP3179 EC₅₀: 17.1 μmol/L; losartan EC₅₀: >50 μmol/L). Consistent with the activation of PPAR-γ, EXP3179 potently induced 3T3-L1 adipocyte differentiation, a typical PPAR-γ–dependent cell function, and markedly stimulated PPAR-γ target gene expression. EXP3174 failed to regulate differentiation or PPAR-γ target gene expression. The present study characterizes the active losartan metabolite EXP3179 as a partial PPAR-γ agonist. PPAR-γ activation by EXP3179 may help us to understand the beneficial metabolic effects of losartan observed in clinical trials. (Hypertension. 2006;47[part 2]:1-4.)

Key Words: diabetes mellitus ■ insulin resistance ■ angiotensin antagonists

The Losartan Intervention For End point reduction in hypertension (LIFE) study has shown that hypertensive patients receiving the angiotensin type 1 receptor blocker (ARB) losartan have a 25%-lower rate of new-onset diabetes than patients treated with the β-blocker atenolol. Although these data suggest a possible antidiabetic action of losartan, the molecular mechanisms are widely unknown.

We and others recently demonstrated that a subset of ARBs, including losartan, induces the activity of a nuclear hormone receptor named peroxisome proliferator–activated receptor γ (PPAR-γ) by partial agonism. The direct activation of the ligand-binding domain of PPAR-γ by ARBs is independent of their angiotensin type 1 receptor (AT₁R) blocking actions. PPAR-γ functions as a transcriptional regulator in adipose tissue where it regulates multiple genes involved in lipid and glucose metabolism. Activated by synthetic full agonists like thiazolidinediones/glitazones, PPAR-γ markedly improves whole-body insulin sensitivity resulting in decreased levels of fasting plasma glucose, fasting plasma insulin, and plasma triglycerides. Thus, PPAR-γ activation by ARBs presents a promising molecular mechanism for metabolic actions of these compounds.

Losartan induced PPAR-γ activity only at high concentrations in vitro. Losartan is hepatically metabolized by the cytochrome-P450 pathway and exerts its antihypertensive actions in vivo predominantly by its main metabolite, EXP3174 (Figure 1). During hepatic metabolism of losartan, additional active metabolites are produced, including EXP3179 (Figure 1). This metabolite has a significant molecular homology with indomethacin, an antiinflammatory cyclooxygenase (COX) inhibitor, and mediates a variety of AT₁R-independent, pleiotropic functions (eg, inhibition of platelet aggregation, endothelial adhesion molecule expression, etc.) Indomethacin has been also identified as an activator of PPAR-γ. Given the structural homology of indomethacin and EXP3179, it is likely that EXP3179 has

Received September 28, 2005; first decision October 11, 2005; revision accepted November 2, 2005.

From the Center for Cardiovascular Research (M.S., L.D.L., N.F., T.U., U.K.), Institute of Pharmacology and Toxicology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Division of Endocrinology, Diabetes, and Metabolism (M.S.), Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa; and Technical University (S.U., B.S.), Institute for Organic Chemistry and Biochemistry, Darmstadt, Germany.

T.U. has been a member of the advisory boards and speakers bureau of Boehringer, MSD, Abbot, Novartis, Sanofi-Aventis, and Takeda. T.U. has received research grants from Boehringer, MSD, Novartis, and Takeda. U.K. has received research grants from Boehringer, and Glaxo-Smith-Kline. B.S. has received research grants from Novartis and Schering AG.

Correspondence to Ulrich Kintscher, Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charité Campus Mitte, Universitätsmedizin Berlin, Hessische Str 3/4, 10115 Berlin, Germany. E-mail ulrich.kintscher@charite.de

© 2005 American Heart Association, Inc.

Hypertension is available at http://www.hypertensionaha.org

DOI: 10.11611161.01.HYP.0000196946.79674.8b
also PPAR-γ–binding properties. We hypothesized that the PPAR-γ–activating properties of losartan in vivo might be enhanced by its active metabolites and that PPAR-γ activation by losartan metabolites may provide a potential mechanism of the antidiabetic actions of losartan observed in clinical trials.

Methods

Cell Culture

3T3-L1 adipocytes were differentiated as described previously in the absence of 3-isobutyl-1-methylxanthine. After 9 days, Oil-Red-O staining was performed to assess lipid accumulation. COS-7 cells were purchased from American Type Culture Collection.

Synthesis of EXP3179

The in vitro synthesis of EXP3179 has been described previously. In brief, EXP3179 was synthesized from losartan by incubation with RuCl₃ and H₂O₂ in MeCN followed by liquid chromatography purification.

Transfection and Luciferase Assay

Transient transfection and luciferase assays were performed as described previously. COS-7 cells were transfected using Lipofectamine 2000 (Invitrogen) with pGal4-human [h] PPARγDEF (hPPAR-γ ligand-binding domain [LBD] fused to Gal4 DBD) and pGal5-TK-pGL3 kindly provided by Bart Staels (UR 545 INSERM), and 10 ng pRL-CMV, a renilla luciferase control reporter vector. After 4 hours, transfection medium was replaced by 10% FBS DMEM plus the indicated compounds or vehicle (dimethylsulfoxide), and luciferase activity was measured after 24 hours.

Quantitative Real-Time PCR

Real-time PCR was performed as described previously with an ABI 7000 sequence detection system. Day-8 adipocytes were serum starved overnight, incubated with compounds for 24 hours, and RNA was isolated. Mouse 18S ribosomal RNA was chosen as endogenous controls (housekeeping genes).

Statistical Analysis

ANOVA and t test were performed for statistical analysis as appropriate. Statistical significance was designated at P<0.05. Values are expressed as mean±SD.

Results

EXP3179 Enhances 3T3-L1 Adipocyte Differentiation

To examine whether losartan metabolites regulate a PPAR-γ–mediated cell function, differentiation of 3T3-L1 adipocytes was studied in the presence and absence of losartan, EXP3174, EXP3179, and pioglitazone. EXP3179 (10 μmol/L) potently promoted 3T3-L1 adipocyte differentiation as indicated by an increased lipid accumulation assessed with Oil-Red-O staining (Figure 2A and 2B). In similar concentrations, losartan (10 μmol/L) weakly induced lipid accumulation, and the losartan metabolite EXP3174 had no effect (Figure 2A and 2B). Concentration-response experiments revealed that EXP3179-mediated 3T3-L1 adipocyte differentiation started between 1 and 10 μmol/L (Figure 2B). Losartan markedly enhanced the differentiation process only at high concentrations (100 μmol/L; Figure 2B).

EXP3179 Induces PPAR-γ Target Gene Expression

Consistent with the stimulation of adipocyte differentiation, EXP3179 (10 μmol/L) induced mRNA expression of the adipogenic marker and PPAR-γ target gene, adipose protein 2, in 3T3-L1 adipocytes (Figure 3A). Losartan and EXP3174 at 10-μmol/L concentrations had no effect on adipose protein 2 mRNA expression.

A specific characteristic of agonists for PPAR-γ is the downregulation of the receptor on mRNA and/or the protein...
level in adipocytes on ligand activation in an autoregulatory manner. To additionally characterize EXP3179 as a PPAR-\(\gamma\)/H9253 activator, we studied the regulation of PPAR-\(\gamma\)/H9253 mRNA expression in 3T3-L1 adipocytes under stimulation with losartan metabolites. In line with pioglitazone-mediated PPAR-\(\gamma\)/H9253 downregulation, EXP3179 significantly downregulated PPAR-\(\gamma\)/H9253 mRNA expression in 3T3-L1 adipocytes, whereas losartan and EXP3174 had no effect (Figure 3B).

**EXP3179 Activates the PPAR-\(\gamma\) Ligand-Binding Domain**

To prove that EXP3179 activates PPAR-\(\gamma\), we assessed its ability to directly activate the PPAR-\(\gamma\) LBD by using a chimeric Gal4-DBD-hPPAR-\(\gamma\)-LBD fusion protein on a Gal4-dependent luciferase reporter. EXP3179 prominently induced the activation of the PPAR-\(\gamma\) LBD reaching a maximum at 100 \(\mu\)mol/L with a 7.1 \(\pm\)1-fold induction (\(P<0.05\) versus vehicle-treated cells; Figure 4). Maximum PPAR-\(\gamma\) LBD activation by EXP3179 reached 51% of the maximum response induced by the full PPAR-\(\gamma\) agonist pioglitazone, identifying EXP3179 as a partial PPAR-\(\gamma\) agonist (Figure 4). EXP3174 did not induce PPAR-\(\gamma\) LBD activation (Figure 4). EC\(_{50}\) values were calculated for PPAR-\(\gamma\) LBD activity (pioglitazone EC\(_{50}\): 0.88 \(\mu\)mol/L; EXP3179 EC\(_{50}\): 17.1 \(\mu\)mol/L; and losartan EC\(_{50}\): >50 \(\mu\)mol/L).

**Discussion**

This study identifies the active losartan metabolite EXP3179 as a partial PPAR-\(\gamma\) agonist. EXP3179 markedly promotes 3T3-L1 adipocyte differentiation, induces PPAR-\(\gamma\) target gene expression, and directly activates the PPAR-\(\gamma\) LBD. PPAR-\(\gamma\) activation by EXP3179 may provide a mechanism for the beneficial antidiabetic actions of losartan observed in clinical trials.

Losartan is a prodrug that is actively metabolized by the cytochrome P450 isoenzyme CYP2C9 on first liver passage to its main antihypertensive metabolite, EXP3174. EXP3174 is 10-fold to 40-fold more potent compared with losartan and mediates most of the AT\(R\)-blocking effects of losartan. Recently, an important intermediate aldehyde metabolite of losartan, EXP3179, has been identified. In contrast to EXP3174, EXP3179 has very little AT\(R\)-blocking activity and has been hypothesized to mediate pleiotropic actions of losartan observed in clinical and animal studies. Kramer et al\(^7\) demonstrated that EXP3179 potently inhibits the expression of endothelial COX-2, thereby exerting potent antiinflammatory actions. In addition, Watanabe et al\(^8\) showed that EXP3179 stimulates endothelial NO synthase phosphorylation and suppresses endothelial cell apoptosis induced by tumor necrosis factor \(\alpha\) independent of AT\(R\)-mediated signaling. The molecular mechanism underlying these pleiotropic EXP3179 actions are unknown. Ligand-activated PPAR-\(\gamma\) exerts potent antiinflammatory actions by inhibiting the action of proinflammatory transcription factors, such as AP-1 and nuclear factor \(\kappa\)B. \(^{11}\) Activation of PPAR-\(\gamma\) has also been shown to repress COX-2 promoter activity and mRNA expression by interacting with the c-jun component of the AP-1 complex. \(^{12}\) EXP3179-mediated activation of PPAR-\(\gamma\) may, therefore, provide a new mechanism of the observed antiinflammatory actions of this compound.

EXP3179 induced PPAR-\(\gamma\) activation as a partial agonist, which implies the consideration of whether the compound may antagonize the actions of a full glitazone agonist during
cotreatment. We performed experiments with another PPAR-γ-activating ARB, telmisartan, in the absence and presence of pioglitazone analyzing the activation of the PPAR-γ LBD in vitro (M. Schupp and U. Kintscher, unpublished data, 2005). These results demonstrated that telmisartan attenuates pioglitazone-induced PPAR-γ activation only at concentrations >10 μmol/L, a concentration that is usually not achieved in patients treated with antihipertensive doses. Because telmisartan is the most potent PPAR-γ-activating ARB, antagonistic actions of these substances on glitazone-induced PPAR-γ activation are unlikely to play a role in vivo or in clinical routine. Furthermore, we demonstrated recently that PPAR-γ-activating ARBs, such as telmisartan and irbesartan, act like selective PPAR-γ modulators compared with the full agonist pioglitazone involving distinct PPAR-γ coactivator binding and induction of distinct gene expression profiles in adipocytes. EXP3179 behaves similar to telmisartan and irbesartan in differentiation assays, adipogenic gene regulation, and transactivation assays, which implicates that EXP3179 may also exert selective PPAR-γ modulator activity.

In clinical trials, losartan has been shown to mediate prominent antidiabetic actions, such as a marked reduction of new-onset diabetes. The molecular mechanism of these metabolic actions is still far from being understood. It is now well known that blockade of AT1R results in multiple beneficial effects on insulin and glucose metabolism mediated via an improvement of muscular and pancreatic blood flow or an inhibition of deleterious angiotensin II actions on insulin signaling. We and others recently demonstrated that certain ARBs act like activators of PPAR-γ, which might contribute to their antidiabetic effects. However, because PPAR-γ activation by losartan was only achieved at very high concentrations, it appears unlikely that PPAR-γ is responsible for the antidiabetic actions of this compound. In contrast, the losartan metabolite EXP3179 induced PPAR-γ activation more potently compared with losartan identifying this metabolite as a possible mediator of the antidiabetic properties of losartan.

The question remains as to whether EXP3179-mediated PPAR-γ activation plays a role in the antidiabetic actions of losartan observed in clinical studies. Kramer et al. reported that after a single oral dose of losartan (100 mg), maximum serum concentrations of EXP3179 between 0.1 and 1 μmol/L were achieved. In the present study, PPAR-γ-mediated adipocyte differentiation, as well as activation of the PPAR-γ LBD by EXP3179, started between 1 and 10 μmol/L. In consideration of the high lipohilicity of EXP3179 rendering it receptive for tissue accumulation and in consideration of an additional increase of serum levels under chronic losartan treatment, EXP3179 concentrations required for PPAR-γ activation may well be reached under losartan treatment. However, rapid hepatic metabolization of EXP3179 has to be taken into account, and additional studies are required to assess whether stable serum and tissue concentrations of EXP3179 are achieved to activate PPAR-γ in patients treated with different doses of losartan.

Perspectives

PPAR-γ activation by EXP3179 may provide a new mechanism of antidiabetic actions induced by losartan. In addition, the identification of an additional PPAR-γ-activating compound with a chemical structure equal to ARBs helps us to understand the characteristic of such substances and supports the development of new dual ARB/PPAR-γ ligands for the treatment of patients experiencing hypertension, insulin resistance, or diabetes.

Acknowledgments

We thank Merck (Rahway, NJ) for kindly providing losartan. T.U. and U.K. are supported by the Deutsche Forschungsgemeinschaft (FK 754). We thank Bart Staels for kindly providing constructs.

References

EXP3179 Inhibits Collagen-Dependent Platelet Activation via Glycoprotein Receptor-VI Independent of AT₁-Receptor Antagonism: Potential Impact on Atherothrombosis
Grothusen: EXP3179 and platelets

Christina Grothusen MD¹, Sumaira Umbreen², Ildiko Konrad³, Konstantinos Stellos MD⁴, Christian Schulz MD³, Boris Schmidt PhD², Elisabeth Kremmer MD⁵, Omke Teebken MD⁶, Steffen Massberg MD³, Maren Luchtefeld PhD¹, Bernhard Schieffer MD⁷, Meinrad Gawaz MD⁴*

¹Abteilung fuer Kardiologie und Angiologie, Medizinische Hochschule Hannover, Germany
²Institut fuer Organische Chemie und Biochemie, Technische Universitaet Darmstadt, Germany
³Deutsches Herzzentrum und 1. Medizinische Klinik, Technische Universitaet Muenchen, Germany
⁴Abteilung fuer Kardiologie und Angiologie, Medizinische Klinik III, Universitaet Tuebingen, Germany
⁵Institut fuer Molekulare Immunologie, GSF-Nationales Forschungszentrum fuer Umwelt und Gesundheit, Muenchen, Germany
⁶Abteilung fuer Thorax- and Kardiovaskulaere Chirurgie, Medizinische Hochschule Hannover, Germany

*Co-contributing senior authors

Corresponding Author:
Bernhard Schieffer, MD,
Abt. fuer Kardiologie und Angiologie,
Medizinische Hochschule Hannover,
Carl-Neuberg-Str. 1, 30625 Hannover, Germany
Phone: +49-511-532-2129,
Fax: +49-511-532 6473,
e-mail: Schieffer.Bernhard@mh-hannover.de

Total word count: 4933
Abstract: 189
Figures: 6
Abstract

Objective: Thrombus formation following atherosclerotic plaque rupture critically involves the platelet collagen receptor glycoprotein (GP)VI. We investigated the impact of EXP3179, an active metabolite of the angiotensin II type 1 (AT₁)-receptor antagonist Losartan (LOS) on GPVI-dependent platelet activation.

Methods and Results: EXP3179 and LOS but not EXP3174 - the major AT₁-receptor blocking metabolite of LOS - dose-dependently inhibited collagen-I and GPVI-dependent platelet aggregation analysed by optical aggregometry (p<0.01). Platelet activation was further determined by flow cytometry measuring the expression of platelet PAC-1, an epitope of the activated fibrinogen-receptor complex. Both, EXP3179 and LOS inhibited collagen-I and GPVI-dependent PAC-1 expression (p<0.01). EXP3174 reduced collagen-I (p<0.05) but not GPVI-dependent PAC-1 expression. EXP3179 and LOS but not EXP3174 decreased the adhesion of GPVI-receptor expressing chinese hamster ovarian (CHO)-cells on collagen-I under shear conditions as analysed by flow chamber (p<0.01). EXP3179 also reduced human atherosclerotic plaque material-induced platelet aggregation (p<0.01) in vitro and murine platelet adhesion after acute vessel injury in vivo as determined by intravital microscopy (p<0.01).

Conclusion: EXP3179 acts as a specific inhibitor of the platelet collagen receptor GPVI independent of AT₁-receptor antagonism. Further investigations may clarify its individual potential as a novel pharmacological approach to specifically inhibit atherothrombotic events by GPVI-receptor blockade.

Condensed Abstract

This study investigated the impact of EXP3179, an active metabolite of Losartan on collagen-induced platelet activation via the GPVI-receptor, which is involved in platelet adhesion to atherosclerotic lesions. EXP3179 inhibits collagen-dependent platelet activation by GPVI-receptor blockade independent of AT₁-receptor antagonism, suggesting a novel role for EXP3179 as a platelet-inhibitory agent.

Keywords: EXP3179, platelets, collagen, GPVI-receptor, atherothombosis
Introduction

Occlusive arterial thrombosis following atherosclerotic plaque rupture represents the major pathophysiological mechanism underlying acute coronary syndromes (ACS) or cerebrovascular events, i.e. stroke. Atherosclerotic plaque rupture injures the integrity of the vascular wall and leads to exposure of highly pro-coagulatory extracellular matrix (ECM) components. These include collagen-I, a major element of the structurally altered ECM in atherosclerotic vessels. The importance of collagen-platelet interactions via the platelet collagen receptor glycoprotein (GP)VI for arterial thrombus formation following vessel injury has recently been recognized by experimental and clinical data. In this regard, GPVI seems to be crucial for thrombus formation in response to platelet contact with human atherosclerotic plaque material \textit{ex vivo} and \textit{in vivo} at sites of murine arterial vascular injury. Subsequently, platelet GPVI-receptor surface expression was found to be elevated in patients with ACS. Thus, blockade of GPVI-receptor activation may represent a novel pharmacological target to inhibit atherothrombotic events following atherosclerotic plaque rupture.

EXP3179 was originally identified as an active metabolite of the angiotensin II type 1 (AT\textsubscript{1})-receptor antagonist Losartan (LOS), which is produced during the hepatic metabolism of LOS by the cytochrome-P450 pathway (figure 1A). We recently reported that EXP3179 is detectable in patients after LOS administration and inhibits platelet activation, even though the underlying mechanisms remained unclear. Current observations from other groups revealed, that EXP3179 activates the endothelial nitric oxide synthase (eNOS) and acts as a peroxisome proliferator-activated receptor (PPAR)-gamma agonist. So far, the potentially beneficial effects of EXP3179 have only been investigated in concomitance and dependence of LOS treatment. In contrast, we here postulated that EXP3179 might possess an individual pharmacological potential independent of LOS application and its impact on the AT\textsubscript{1}-receptor. Therefore, we analysed the effects of EXP3179, LOS and EXP3174 - the main metabolite of LOS and specific AT\textsubscript{1}-receptor antagonist - on collagen-I and GPVI-receptor-dependent platelet activation, adhesion and aggregation and evaluated the impact of EXP3179 on acute platelet adhesion to the injured arterial vessel wall \textit{in vivo}. 

Materials and Methods

Synthesis of EXP3179

The $^1$H- and $^{13}$C NMR spectra were recorded on a Bruker AC 300 spectrometer at 300 (75). Chemical shifts are reported as % values (ppm) downfield from Me$_4$Si. Mass spectrometry was performed on a Bruker-Franzen Esquire LC mass spectrometer. Flash column chromatography was carried out using Merck silica gel 60 (40-63 and 15-40 $\mu$m) and 60G (5-40 $\mu$m). Thin-layer chromatography (TLC) was carried out using aluminum sheets precoated with silica gel 60 F$_{254}$ (0.2 mm; Merck, Germany). Chromatographic spots were visualized by UV and/or spraying with an acidic, ethanolic solution of p-anisaldehyde or an ethanolic solution of ninhydrin followed by heating. IBX (2-iodoxybenzoic acid). All commercial chemicals were used without further purification. EXP3179 was synthesized by a modified protocol, which provides higher yields than the previously reported methods. Losartan (0.422 g, 1 mmol) was oxidized with IBX (2-iodoxybenzoic acid, 0.321 g, 1.2 mmol) in DMSO (5 mL) at room temperature for 6 h. CH$_2$Cl$_2$ (30 mL) was added and the solution was washed with water (3 x 30 mL), NaHCO$_3$ solution (3 x 30 mL, sat.), and brine (1 x 30 mL). The solvent was removed after drying (Na$_2$SO$_4$) to yield the product (410 mg, 98%) EXP3179.

Synthesis of EXP3174 via EXP3179

A mixture of 0.147 g (0.35 mmol) of EXP3179 and 0.287 g (3.3 mmol) of activated manganese dioxide in 2 ml of H$_2$O was refluxed for 78 hrs. The reaction was monitored by TLC (CHCl$_3$/MeOH/CH$_3$COOH 95/5/0.5). Excess of MnO$_2$ was filtered, the solvent was removed under reduced pressure and the residue was purified by acid base workup. EXP3174 (200 mg, yield 56 %)

EXP3179, Losartan and EXP3174 Stock Solutions

EXP3179 was dissolved in 0.05% DMSO (Sigma-Aldrich, USA), 9.95% Tris-HCl and diluted in phosphate buffered saline (PBS, pH 7.4, free of Ca$^{2+}$ and Mg$^{2+}$, Sigma-Aldrich, USA). Losartan was dissolved in PBS (pH 7.4, free of Ca$^{2+}$ and Mg$^{2+}$, Sigma-Aldrich, USA). EXP3174 was dissolved in 10% Tris-HCl and diluted in PBS (pH 7.4, free of Ca$^{2+}$ and Mg$^{2+}$, Sigma-Aldrich, USA).

Blood Samples

Human peripheral venous blood samples were taken with a loose tourniquet to avoid artefacts through a short venous catheter inserted into the forearm of healthy volunteer donors, who had not taken any medication known to interfere with platelet activation for at least 14 days.

Aggregometric Analysis

Platelet aggregation was evaluated by optical aggregometry as described previously. After adjustment to a total platelet count of 2x10$^8$/mL, Platelet-rich plasma (PRP) was incubated with varying doses of EXP3179, LOS, EXP3174 or the corresponding solvents for 15 min. Collagen (type)-I (Probe&Go, Germany) or 4C9 (provided by the GSF-research centre for Environment and Health GmbH, Institute for molecular Immunology, Munich, Germany), a monoclonal GPVI-receptor stimulating antibody were added in varying concentrations to induce platelet
activation. As reported previously, 4C9 detects the GPVI-receptor on the platelet surface. In addition, adenosin-5'-diphosphate (ADP, 5 μmol/L; Probe&Go, Germany) or thrombin-receptor-activating-peptide (TRAP) (25 μmol/L; Sigma-Aldrich, USA) were used to induce platelet activation. To evaluate the impact of EXP3179 on atherosclerotic plaque material-induced platelet aggregation, we followed a protocol recently published by Penz et al. Patient consent was obtained as approved by the Institutional Ethics Committee. For experiments with murine PRP, samples were pooled. Maximal aggregation at 5 min was used as measurement of aggregation.

**Flow Cytometry**

Evaluation of the surface expression of platelet membrane glycoproteins was performed by immunolabeling followed by flow cytometry analysis as described previously. In brief, PRP (adjusted to 2x10⁸ platelets/mL) was incubated with varying doses of EXP3179, LOS, EXP3174 or the corresponding solvents for 30 min. followed by incubation with varying dosages of 4c9 or collagen-I and PAC-1 antibody, an epitope of the activated fibrinogen receptor complex (anti-PAC-1 FITC, Becton Dickinson, USA) for 30 min. Samples were fixed with 0.5% paraformaldehyde and analysed within 2 hours. 10,000 events were analysed. Specific antibody binding was expressed as mean intensity of immunofluorescence.

**Flow Chamber**

ACD (acid citrate dextrose)-anticoagulated whole blood samples were obtained as described previously. Coverslips were coated with collagen-I (20 μg/mL). Platelets were perfused through a flow chamber (Oligene, Germany) mounted on the stage of an Axiovert 100 (Zeiss, Jena, Germany) microscope at high shear rate (1000 sec⁻¹). Images were taken randomly and evaluated offline using a computer-assisted image analysis program (Cap Image 7.1; Zeintl, Germany). The duration of one set of experiments was limited to one hour in order to preserve platelet reactivity. To investigate the impact of EXP3179, LOS and EXP3174 on GPVI-receptor mediated cell adhesion on collagen-I under shear conditions, the Flp-In™ system (Invitrogen, Carlsbad, USA) was used as described elsewhere. In short, the Flp-In™ system was used to generate a CHO-cell line stably expressing the human GPVI-receptor. Non-transfected Flp-In™-CHO-cells served as controls. CHO-GPVI and CHO-cells were cultured using HAM’s F12 containing 10% FCS + 1% penicillin/streptomycin. For culturing the CHO-GPVI cell line 400 μg/mL hygromycin were added. Surface expression of the human GPVI-receptor by CHO-cells was tested by flow cytometry using the anti-GPVI monoclonal antibody 5C4 (see supplementary data, figure 3). Both cell lines were perfused over collagen-I (20 μg/mL) or bovine serum albumin (BSA, 3%) coated glass coverslips in a cell concentration of 500,000/mL at a constant shear rate (1000 sec⁻¹). Experiments were recorded in real time and evaluated off-line using Cap Image software (Cap Image 7.1; Zeintl, Germany).

**Intravital Fluorescence Microscopy**

For intravital fluorescence microscopy (IVM) of the injured carotid artery, 12 weeks old C57BL6/J mice (Charles River; Sulzfeld, Germany) were anaesthetized by intraperitoneal injection of Midazolam (5 mg/kg bodyweight), Medetomidine (0.5 mg/kg bodyweight) and Fentanyl (0.05 mg/kg bodyweight). Murine platelets were isolated from whole blood samples and labelled with 5-(and -6)-carboxyfluorescein diacetate, succinitimidyl ester (DCF). The final platelet concentration was 2x10⁸ in 500μL PRP. After pre-incubation of murine platelets with either EXP3179 or the diluent (15 min), samples were administered via a jugular catheter. Adhesion of
fluorescent platelets was analysed by in situ video microscopy before and after carotid injury caused by ligation of the common carotid artery for 5 min as described previously. Adherent platelets were measured using a computer-assisted programme and are given per mm\(^2\) (Capimage, Zeintl, Germany). All experiments were approved by the Institutional Animal Care and Use committee.

Statistics

Data are given as mean±SD of at least 3 independent experiments. Student’s t-test was used. Data are given as mean±SD. A p-value <0.05 was considered statistically significant. Statistical analysis was performed using SPSS.

Results

EXP3179 and LOS Dose-Dependently Inhibit Collagen-I Induced Aggregation and Activation of Human Platelets

After incubation of PRP with increasing dosages of EXP3179, LOS, EXP3174 or the appropriate solvent platelet aggregation was induced by stimulation with varying collagen-I concentrations and analysed by optical aggregometry. EXP3179 and LOS similarly and dose-dependently inhibited collagen-I-induced aggregation of human platelets, reaching significant effects at a concentration of 500 \(\mu\)M after stimulation of PRP with 1 \(\mu\)g/mL and 2 \(\mu\)g/mL collagen-I (EXP3179 10±6.2%, LOS 20±9%, each vs PRP 63±9%, \(p<0.01\), \(n=3-6\), Figure 1B). In contrast, EXP3174 did not influence collagen-I dependent platelet aggregation. While LOS has already been reported to inhibit ADP or TRAP-dependent platelet aggregation, we did not find any impact on these parameters after pre-incubation of PRP with EXP3179 (Figure 1C).[Guerra-Cuesta, 1999 #61][Schwemmer, 2001 #62]

Platelet activation leads to a rapid conformational change of the GPIIb-IIIa receptor complex enabling soluble plasmatic fibrinogen binding, which is considered as a major step towards platelet aggregation. The impact of EXP3179 on GPIIb-IIIa activation was evaluated by flow cytometry using the conformation-dependent antibody PAC-1, an epitope of the activated fibrinogen receptor complex. Platelets were pre-incubated with increasing dosages of EXP3179, LOS, EXP3174 or the indicated solvent followed by incubation with varying concentrations of collagen-I (for dose-response experiments see supplementary data, figure 1). EXP3179, LOS and - to a lesser extent EXP3174 - dose-dependently reduced the expression of PAC-1 reaching a maximum effect at a concentration of 500 \(\mu\)M after stimulation of PRP with 5 \(\mu\)g/ml collagen-I (EXP3179 11.5±2, \(p<0.01\), LOS 12.9±1.8, \(p<0.01\), EXP3174 33.75±9.9, \(p<0.05\), each vs stimulated (stim) PRP 65.82±19.3, \(n=4-7\), Figure 1D). No difference between administration of solvent and PRP alone was detected (see supplementary data, figure 1). EXP3179 did not affect TRAP- or ADP - induced PAC-1 expression (data not shown).

EXP3179 Reduces Human Platelet Adhesion on Collagen-I under Shear Conditions

Platelet adhesion under dynamic shear conditions - as present in vivo- can be simulated by using a flow chamber. As reported by other groups, LOS and EXP3174 may influence collagen-dependent adhesion of human platelets under flow. To evaluate the impact of EXP3179 on this parameter, whole blood samples were labelled with rhodamin-6G and incubated with solvent or EXP3179. Platelet adhesion was investigated under constant perfusion over collagen-I coated cover slides. EXP3179 significantly inhibited platelet adhesion evaluated under high shear
rate (1000sec⁻¹) (44.7± 14.4% vs. 100%; p<0.01; n=5; Figure 1E) in comparison to solvent administration. As high shear rates are predominantly present in the arterial branches and bifurcations of the cardiovascular system and may play an important role at sites of atherosclerotic lesions,20,22 these results indicate an effective inhibition of platelet adhesion by EXP3179 under pathophysiological arterial flow conditions.

**EXP3179 and LOS Inhibit Human GPVI-Receptor-dependent Platelet Activation and Aggregation**

To further evaluate the potential mechanisms underlying the anti-aggregatory effects of EXP3179 following collagen stimulation, we analysed the impact of EXP3179, LOS and EXP3174 on the activation of the major platelet collagen receptor GPVI. Therefore, human PRP was pre-incubated with EXP3179, LOS or EXP3174 and stimulated with the selective GPVI-receptor activating antibody 4C9, which has been shown to induce platelet activation via GPVI-receptor ligation.23 EXP3179 and LOS dose-dependently inhibited GPVI-dependent platelet aggregation reaching a maximum effect at a concentration of 500 μM after stimulation of PRP with 0.1 μg/mL 4c9. EXP3174 did not have any detectable influence on this parameter (EXP3179 18.8±4.9%; LOS 20±9.6%, each vs PRP 70.3±1%, each p<0.01, Figure 2A). Furthermore, flow cytometry experiments revealed that the 4C9-dependent platelet activation represented by PAC-1 expression was substantially reduced in the presence of EXP3179 and LOS reaching a maximum effect at a concentration of 500 μM after stimulation of PRP with 0.1 μg/mL 4c9 (see supplementary data for dose-response experiments, figure 2) (EXP3179 25.2±5.8, LOS 33.2±9.7, each vs stim PRP 508.4±18.9, each p<0.01, Figure 2B). EXP3174 did not significantly influence 4c9-dependent platelet activation. We did not detect any difference between administration of solvent and PRP alone (see supplementary data, figure 2).

**EXP3179 and LOS Inhibit GPVI-Receptor Dependent Cell Adhesion on Collagen-I under Shear Conditions**

To further specify the influence of EXP3179 on GPVI-receptor dependent cell adhesion under shear conditions, GPVI-receptor-expressing CHO cells were used as previously described.7 EXP3179 and LOS but not EXP3174 (each used in a concentration of 500 μM) significantly inhibited the adhesion of CHO-GPVI cells on collagen-I coated cover slips in comparison to incubation with solvent (see supplementary data, figure 4) or untreated cells (EXP3179 14.3±9 vs 40.9±8.7, p<0.01, LOS 30.1±9.7, p<0.05, each vs 40.9±8.7 untreated CHO-GPVI cells cells/mm², n=3, Figure 3). Neither EXP3179 nor LOS influenced the adhesion of control CHO-F cells (see supplementary data, figure 5).

**EXP3179 Decreases Human Platelet Aggregation after Stimulation with Human Atherosclerotic Plaque Material**

Thrombus formation at sites of atherosclerotic lesions seems to be critically influenced by collagen-induced platelet adhesion via GPVI-receptor activation.9 Therefore, we investigated the impact of EXP3179 on platelet aggregation in response to components of human carotid atherosclerotic plaques ex vivo by aggregometry. After incubation with solvent or EXP3179, PRP was stimulated with homogenized atherosclerotic plaque material from patients who had undergone carotid thrombendarterectomy. EXP3179 significantly inhibited platelet aggregation
following stimulation with human plaque homogenates (18.7±19.8% vs 56.7±16.7%; p<0.01; n=4; Figure 4) compared to solvent.

**EXP 3179 Reduces Murine Platelet Aggregation in vitro and Platelet Adhesion in vivo**

Stable murine platelet adhesion and aggregation at sites of acute vessel injury in vivo are substantially influenced by GPVI-receptor availability. Therefore, we evaluated the impact of EXP3179 on murine platelet aggregation and adhesion. To investigate potential species-specific differences of EXP3179, murine platelet aggregation was first investigated ex vivo. As shown for human platelets, EXP3179 significantly inhibited murine platelet aggregation after stimulation with collagen-I in comparison to PBS (data not shown) or solvent administration (25.3±24.8% vs 79.5±7.6%; p<0.01; n=8 animals, PRP was pooled for 3 experiments; Figure 5A). To evaluate the influence of EXP3179 on murine platelet activation in vivo, a mouse model of carotid injury was used and platelet adhesion at the site of injury was visualized by intravital fluorescence microscopy, as described previously. Murine DCF-labelled platelets were pre-incubated with EXP3179 or solvent and administered via a venous catheter. Carotid injury was induced by ligature of the common carotid artery as described elsewhere. EXP3179 significantly reduced platelet adhesion to the site of injury in comparison to solvent administration. (Figure 5B, 1061.5±298.1 vs 2047.0±692.2 adherent platelets/mm²; p<0.01; n=6/group).

**Discussion**

Here we identify EXP3179 as an individual and selective inhibitor of GPVI-receptor dependent platelet activation and aggregation in vitro and in vivo independent of AT₁-receptor antagonism.

Acute vessel injury by atherosclerotic plaque rupture exposes pro-coagulatory elements of the subendothelial ECM to circulating platelets, which are instantly activated. Subsequently, occlusive arterial thrombosis may occur and result in ACS or stroke. In this regard, collagen-I is one of the major pro-coagulant ECM components in atherosclerotic vessels, which plays a critical role for stable platelet adhesion at the site of injury. The major platelet collagen receptor is considered to be GPVI as suggested by recent experimental and clinical evidence showing the importance of GPVI-receptor activation in collagen-dependent platelet adhesion and thrombus formation, both in vitro and in vivo. Interestingly, activation of GPVI may especially be critical for thrombotic events following atherosclerotic plaque rupture. Thus, inhibition of GPVI-receptor activation may represent a novel pharmacological target in the search of more selective and specific anti-thrombotic agents for the prevention and/or treatment of acute occlusive arterial thrombosis, e.g. myocardial infarction or stroke.

Blockade of the renin-angiotensin system (RAS) by AT₁-receptor antagonists such as LOS effectively reduce the incidence of cardiovascular events as demonstrated by large scale clinical trials. This impact seemingly involves the generation of active metabolites, i.e. EXP3179 or EXP3174. Based on recent observations which revealed various potentially vasoprotective effects of EXP3179, we hypothesised, that EXP3179 might possess an individual pharmacological potency, which may not only contribute to the beneficial effects of LOS but qualify EXP3179 as an independent candidate for future treatment strategies to prevent acute atherothrombosis. Here, we demonstrate that EXP3179 selectively reduces collagen-dependent human platelet activation, adhesion and aggregation independent of AT₁-receptor antagonism. In this regard, Kalinowski et al. already reported that application of LOS itself impairs collagen-induced platelet aggregation.
and adhesion, which was attributed to a release of NO.\textsuperscript{21} Indeed, Watanabe et al. recently identified EXP3179 as a potent activator of the eNOS phosphorylation.\textsuperscript{12} In platelets, however, the role of eNOS remains controversially discussed. Furthermore, eNOS-associated signalling involves not only collagen-related but also alternative pathways, e.g. thrombin or ADP, both of which were not seen to be influenced by EXP3179 in the present study.\textsuperscript{26-30} Instead, we show that EXP3179 markedly inhibited GPVI-receptor-mediated platelet aggregation and activation as determined by platelet PAC-1 expression. Furthermore, EXP3179 - in contrast to the main LOS metabolite EXP3174 - substantially reduced the adhesion of GPVI-receptor expressing CHO-cells on collagen-I under shear conditions confirming the specific impact of EXP3179 on GPVI-receptor function. Although the relevance of GPVI-receptor activation in experimental murine arterial thrombosis has lately been critically discussed,\textsuperscript{31} recent observations by Penz et al. again emphasized the importance of collagen-dependent platelet activation via the GPVI-receptor for acute thrombus formation at sites of human atherosclerotic lesions.\textsuperscript{9} Therefore, we here investigated - in addition to the \textit{in vitro} experiments - the direct impact of EXP3179 on platelet aggregation induced by human atheromatous plaque material. We were able to demonstrate, that EXP3179 inhibits thrombus formation after stimulation with human plaque material. To evaluate the effect of EXP3179 on platelet adhesion and aggregation \textit{in vivo} we used an established mouse model of carotid injury. In this regard, we - and others - reported that murine thrombus formation in this model crucially depends on GPVI-receptor activation.\textsuperscript{3,7} Here, we show, that EXP3179 substantially reduces platelet adhesion in response to vessel injury underlining the impact on GPVI-receptor-mediated platelet activation by EXP3179 also \textit{in vivo}.

\textbf{Study limitations and Clinical Perspectives}

Before the onset of the study presented, the pharmacokinetics and – dynamics of EXP3179 \textit{in vivo} had only been investigated once and in context of a single orally - applied dose of LOS.\textsuperscript{11} Thus, we are the first to consider and apply EXP3179 as an individual potential drug. Although we did not observe any signs of acute intoxication or obvious signs of un-specificity (compared to solvent) when using EXP3179 in micromolar concentrations, further studies will be needed to establish a dose-dependent pharmaco-toxicological profile of EXP3179.\textsuperscript{13} To summarize, this study describes EXP3179 as a potent inhibitor of collagen-dependent platelet activation, aggregation and adhesion via GPVI \textit{in vitro} and \textit{in vivo}. These results indicate EXP3179 as an individual platelet-inhibitory and potentially vasoprotective agent in the experimental attempt to identify new therapeutic strategies to prevent fatal atherothrombotic cardiovascular events.

\textbf{Acknowledgments}

We would like to thank Sandra Kerstan, Iris Schäfer, Lothar Grote and Mirja Sirisko for their excellent technical support. This work is supported by the Deutsche Forschungsgemeinschaft grant Schie 386/7-2.

\textbf{Conflict of Interest Disclosure}

The authors have nothing to disclose.
References


Figure Legends

**Figure 1:** A: Molecular structure of EXP3179. B: Impact of EXP3179, LOS and EXP3174 on collagen-I induced human platelet aggregation. Incubation of PRP with EXP3179, LOS, or appropriate solvent led to a dose-dependent inhibition of collagen-I-induced aggregation of human platelets. A significant effect was observed at a concentration of 500 μM after stimulation of PRP with 1 μg/mL or 2 μg/mL collagen-I. EXP3174 had no impact on this parameter. Data are given as maximal aggregation in % and were analysed by optical aggregometry. Data are mean±SD; *p<0.01 vs PRP/solvent; n=5-8 C: EXP3179 in a concentration of 500 μM did not influence TRAP- or ADP-induced platelet aggregation. D: Incubation of human PRP with EXP3179, LOS, or appropriate solvent followed by stimulation with collagen-I led to a reduction of platelet PAC-1 expression analysed by flow cytometry. The maximum effect was observed at a concentration of 500 μM after stimulation of PRP with 5 μg/mL collagen. Specific antibody binding was expressed as mean intensity of immunofluorescence. Data are mean±SD; #p<0.05 vs stimulated (stim) PRP; *p<0.01 vs stim. PRP; n=4-7 E: Impact of EXP3179 on human platelet adhesion under high shear conditions. Whole-blood samples were incubated with solvent or EXP3179 followed by perfusion (1000sec⁻¹) over collagen-I coated cover slides. EXP3179 significantly inhibited platelet adhesion on collagen-I under shear conditions. Data are given as relative platelet adhesion in %. Data are mean±SD; *p<0.01 vs solvent; n=5

**Figure 2:** Impact of EXP3179, LOS and EXP3174 on GPVI-receptor-dependent human platelet aggregation and activation A: Incubation of PRP with EXP3179, LOS, EXP3174 or appropriate solvent was followed by stimulation with 4C9, a GPVI-receptor-activating antibody. EXP3179 and LOS dose-dependently inhibited GPVI-dependent human platelet aggregation analysed by optical aggregometry. The maximum effect was observed at a concentration of 500 μM after stimulation of PRP with 0.1 μg/mL 4c9. EXP3174 did not affect this parameter. Data are given as maximal aggregation in %. Data are mean±SD; *p<0.01 vs PRP; #p<0.05 vs PRP; n=5-8 B: Incubation of human PRP with EXP3179, LOS or appropriate solvent followed by stimulation with 4C9 led to a reduction of platelet PAC-1 expression as analysed by flow cytometry. The maximum effect was observed at a concentration of 500 μM after stimulation of PRP with 0.1μg/mL 4c9. EXP3174 did not have a significant impact on GPVI-dependent PAC-1 expression. Specific antibody binding was expressed as mean intensity of immunofluorescence. Data are mean±SD; *p<0.01 vs stimulated (stim) PRP; n=3-7

**Figure 3:** Impact of EXP3179, LOS and EXP3174 on GPVI-receptor-dependent cell adhesion under shear conditions. CHO-GPVI or CHO-F cells were incubated with EXP3179, LOS, EXP3174 or appropriate solvent followed by perfusion (1000sec⁻¹) over collagen-I or BSA coated cover slides. Incubation of CHO-GPVI cells with EXP3179 and LOS led to a reduction of cell adhesion on collagen-I matrices under shear conditions. EXP3174 did not influence this parameter. Data are mean±SD; *p<0.01 vs CHO-GPVI adhesion on BSA/glass; **p<0.01 vs CHO-GPVI adhesion on collagen-I; #p<0.05 vs CHO-GPVI adhesion on collagen-I; n=3-7

**Figure 4:** Impact of EXP3179 on atherosclerotic plaque material-induced platelet aggregation. Incubation of human platelets with EXP3179 led to a significant reduction of atherosclerotic plaque material-induced platelet aggregation in comparison to administration of solvent analysed by optical aggregometry. Data are given as maximal aggregation in %. Data are mean±SD; *p<0.01 vs solvent; n=4

**Figure 5:** Effects of EXP3179 on murine platelet aggregation in vitro and platelet adhesion in vivo. A: Incubation of murine PRP with solvent or EXP3179 reduced
collagen-I-induced platelet aggregation analysed by optical aggregometry. PRP was pooled, using PRP of 8 animals for n=3 experiments. Data are mean±SD; *p<0.01 vs solvent; n=3

B: Intravital fluorescent microscopy after ligature of the common carotid artery showed a reduction of murine platelet adherence at the site of injury after pre-incubation of murine PRP with EXP3179 and application via a venous catheter in comparison to solvent administration in vivo. Data are mean±SD; *p<0.01 vs solvent; n=6
Figure 1C

Figure 1D

Figure 1E
Figure 2A
Figure 2B:

Figure 3:

Figure 4:
Figure 5A

Figure 5B
Title:

Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release

Authors:

Lusine Danielyan1*, Ali Lourhmati1, Stephan Verleysdonk2, Barbara Proksch1, Sumaira Umbreen3, Boris Schmidt3, Christoph H. Gleiter1

1Department of Clinical Pharmacology, University Hospital of Tuebingen, Tuebingen, Germany
2Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen, Germany.
3Clemens Schoepf-Institute for Organic Chemistry and Biochemistry, Darmstadt, Germany.

*Corresponding Author: L. Danielyan, Department of Clinical Pharmacology, University Hospital of Tuebingen, Otfried-Mueller Strasse 45, 72076 Tuebingen, Germany
Phone: +49-7071-2974926;
Fax: +49-7071-295035;
e-mail: lusine.danielyan@med.uni-tuebingen.de

Running head: Angiotensin receptor type 1 blockade protects astroglia upon hypoxia
Abstract
Despite a multitude of data showing an involvement of the local angiotensin receptor system in neuronal development and survival, little is known about its role for the survival and inflammatory response of astrocytes upon different kinds of injury. Here we show that the AT-R type1 (AT1-R) antagonist losartan and its active metabolite EXP3174 increase the viability of cells in astroglial primary cultures (APC) in a concentration-dependent manner under hypoxic conditions (HC), as determined by LDH release (45±6% decrease). Under HC, APC released 3.5-fold more TNF-alpha than under normoxic conditions (NC). Losartan was capable of decreasing TNF-alpha release under HC (40±15% decrease), alone and in combination with angiotensin II (ATII), while EXP3174 was dependent on ATII for this effect. These data suggest that AT1-R blockade may decrease the susceptibility of astrocytes to hypoxic injury and their propensity to release TNF-alpha. Therefore, AT1-R antagonists may be of therapeutic value during hypoxia-associated neurodegeneration.

Keywords
Hypoxia, angiotensin, neurodegeneration, astrocytes, losartan, EXP3174.
Introduction

Ischemic injury of the brain leads to versatile pathological and defensive processes such as neuronal death, inflammation and activation of microglia as well as astrocytes. Due to their multiple protective features, for instance synthesis of neuroprotective factors such as erythropoietin (1) or vascular endothelial growth factor (2) and maintenance of the extracellular glutamate concentration (3), astrocytes may determine the extent of neuronal damage under hypoxic/ischemic injury. Despite numerous studies demonstrating the critical role of astrocytic apoptosis in the pathogenesis of acute and chronic disorders, such as cerebral ischemia or Alzheimer’s disease (4, 5), the mechanisms regulating astrocytic survival and their capacity to counteract pathological situations are not well understood.

There is increasing evidence for the involvement of the local angiotensin receptor system (ARS) in development, survival and regeneration of neurons. Angiotensin II (ATII) promotes their differentiation and survival in vitro via its receptor subtype 2 (AT2-R) (6) and attenuates hypoxia-induced apoptosis in primary cortical neuronal cultures (7). However, little is known about the role of the ARS in the survival of astrocytes upon different kinds of brain injury. Astrocytes produce ATII and both types of its receptors (AT1-R and AT2-R) (8). ATII promotes the proliferation of different cell types including astrocytes (9, 10), and is upregulated together with its AT2-R after ischemic brain injury (11). The data concerning the effects of ATII during ischemic damage are contradictory: Whilst exogenous application of ATII or AT2-R stimulation decreases the mortality rate in gerbils with unilateral carotid ligation (12, 13) and the long term blockade of AT1-R in rat brain improves the neurological outcome and reduces the infarct volume after experimental ischemia (14), ATII also mediates programmed cell death through AT2-R in different cell types (15). So far, the mechanisms of ATII action on the different CNS cell types and the involvement of its receptor subtypes in protective and pathophysiological mechanisms during hypoxia-associated injury of the brain are still poorly understood.

Selective AT1-R blockade by losartan and other AT1-R antagonists is widely used in treatment of hypertension, a key factor in the pathophysiology of stroke. Although losartan itself is a potent AT1-R antagonist, its antihypertensive action appears to be primarily due to its active metabolite EXP3174 (16). Polidori et al. (17) have shown a delayed effect of intraperitoneally delivered losartan on central targets of angiotensin action, such as water intake, and that the peripheral administration of EXP3174 inhibited water drinking with higher potency than losartan itself. AT1-R blockade was shown to improve the brain microcirculation and therefore to decrease the vulnerability to brain ischemia and stroke in chronically hypertensive rats (18). It suppresses the inflammation of brain vessels in spontaneously hypertensive rats (19) and prevents stress-induced gastric ulcers, in part by reducing inflammation in the gastric mucosa (20), suggesting the involvement of AT1-R in inflammation connected to different kinds of disorders such as ischemia or stress. Inflammation occurs in early stages of acute and chronic neurodegenerative disorders such as stroke or Parkinson’s and Alzheimer’s disease (21, 22). A self-amplifying cycle involving brain immune cells (microglia and astrocytes) has been discussed as one of the mechanisms of these inflammation processes. Several attempts have been made to investigate the role of the local angiotensin receptor system in survival of neurons upon different kinds of injury: While losartan is known to increase the protection of neurons provided by ATII against hypoxia- and rotenone-induced cell death (7, 23), the possible cytoprotective and anti-inflammatory effect of AT1-R antagonists on astrocytes remained unexplored prior to this study. Here, the influence of losartan
and its main active metabolite, EXP3174, on hypoxia-induced damage to astrocytes and on their inflammatory response to hypoxic injury has been investigated.

Experimental Procedure

Cell culture
Astroglial primary cultures (APC) were prepared from the brains of newborn Wistar rats as described elsewhere (24). For the cell viability assay, the cells were grown in 96-well microplates (20000 cells/well), whereas for the multiplex assay of interleukins, 1x10⁶ cells were grown in petri dishes (60 mm in diameter). The cells were cultured in Dulbecco's modified Eagle's medium containing 10% foetal calf serum, 100 μg/ml streptomycin sulphate and 100 units/ml penicillin at 37°C in an incubator containing an atmosphere of 10% CO₂ in air until day 8 in vitro (DIV, day in vitro). On DIV 8 the medium was removed and fresh medium containing different supplements was added. The samples were assayed as described below.

Synthesis of EXP3174 via EXP3179
EXP3179 was synthesized by previously reported methods (25, 26) and oxidized further to EXP3174 by activated manganese dioxide in H₂O under reflux for 78 hrs. Excess of MnO₂ was filtered, the solvent was removed in vacuo and the residue (EXP3174, 200 mg, yield 56 %) was purified by acid/base workup (27).

Incubation with Losartan, EXP3174 and ATII under normoxic and hypoxic conditions
8 day-old cultures were treated for 48 h either with two different concentrations of losartan (100nM or 1μM) kindly provided by MSD SHARP&DOHME (Haar, Germany) or EXP3174 (100nM, 1μM) alone and in combination with 100nM ATII (Sigma, Deisenhofen, Germany). Losartan and ATII were dissolved in phosphate-buffered saline (PBS), EXP3174 was dissolved in DMSO and further diluted with PBS (0.029% final concentration of DMSO). It was previously shown that the viability of astroglial primary cultures is not affected by this DMSO concentration (28). Cells were cultured for 48h at 37°C either under NC with 10% CO₂ in air or under hypoxic conditions (HC) with 1% O₂, 10% CO₂ and 89% N₂.

Cell viability assay
Cell death induced by culture conditions and hypoxia was measured in terms of LDH activity in supernatants of cells grown in 96-well microplates. The experiments were performed following the protocol accompanying the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, USA). Briefly, 50 μl of standards or 50 μl of culture supernatant (controls and treated cells) and 50 μl of substrate mix were transferred into a 96-well-plate and incubated for 30 minutes at room temperature. The enzymatic conversion of tetrazolium salt into red formazan product was stopped by 50 μl stop solution. Plates were read out with a SUNRISE Elisa-plate Reader (Tecan, Crailsheim, Germany) at 490 nm. LDH released from the cells was expressed as a percentage of total cellular LDH, which was measured after lysis of the cells by addition of Triton X-100 to a final concentration of 0,1% in each well.
Multiplex analysis of cytokines.

At DIV 8 the medium was removed from cells grown in petri dishes and fresh medium containing either 1 μM losartan, 1 μM EXP3174 or 1 μM EXP3174 and 100nM ATII was added. The cells were then further incubated for 48h under NC or HC. Subsequently, 50 μl from each dish used for detection of interleukin-4 (IL-4), IL-5, granulocyte-macrophage-colony-stimulating factor (GM-CSF), interferon-gamma (IFNγ) and tumor necrosis factor-alpha (TNFα). The quantification of these cytokines was performed with a Beadlyte® Rat Multi-Cytokine Beadmaster™ Kit (Upstate, Lake Placid, NY) and a Luminex-100 system (Luminex Corporation, Austin, TX) according to the manufacturer’s instructions. The cytokine concentrations in cell culture supernatants were extrapolated from their respective standard curves by 5-parameter logistic analysis (29).

Statistical analyses

Data presented as mean ± SEM (n=6) were normalized to the mean of corresponding controls (normoxic and hypoxic controls) and converted to percentage of control. P <0.05 was considered as significant (* p<0.05; ** p<0.01 , *** p<0,001). To compare the treated samples with controls, one way ANOVA with Dunett’s post comparison test was used.

Results

LDH release as a measure for cell damage was investigated under NC and HC in APC incubated with ATII, Losartan, and EXP3174. Under NC, the application of 100nM and 1μM losartan reduced the release of LDH in a concentration-dependent manner: application of 1μM losartan appeared to be more effective than 100nM losartan (Fig. 1A 100nM L, 1μM L vs. N). The administration of 100nM EXP3174 reduced LDH by 35±11% (Fig. 1A, 100nM EXP), whereas the application of 1μM EXP3174 resulted in a 52±16% decrease of released LDH (Fig. 1A, 1μM EXP).

Simultaneous administration of 100nM ATII and 1μM EXP3174 brought no additional decrease of LDH-release (63±14%, Fig 1A, AT+EXP) when compared with the effect of 1μM EXP3174 applied alone (52±16%, Fig. 1A, 1μM EXP).

Under HC, 100nM of either EXP3174 or losartan had no effect on release of LDH (Fig. 1B, 100nM L and 100nM EXP) when compared with the hypoxic control (Fig. 1B, H). The reduction in LDH release after application of 1μM losartan (37±19 %, Fig. 1B, 1μM L) was similar to that of either 1μM EXP alone (45±6%, Fig. 1B, 1μM EXP) or EXP3174 in combination with ATII (41±6%, Fig. 1B, AT+1μM EXP).

The concentrations of the inflammatory cytokines IL-4, IL-5, GM-CSF and IFNγ in the cell culture supernatants were far below the detection range (< 14 pg/ml) under both NC and HC. Only TNFα was measurable under NC and 3.5-fold up-regulated upon exposure of the cells to hypoxia (cf. N in Fig. 2A with H in B). The effect of 1μM losartan on TNFα-release under NC (33±10%; Fig. 2A, N+L) was slightly lower than that of 1μM EXP3174 (41±15%; Fig.2A: N+EXP vs. N) in comparison to the normoxic control (N in Fig. 2 A). The effect achieved by simultaneous application of 100nM ATII and 1μM EXP3174 or losartan (N+AT+EXP and N+AT+L in Fig. 2 A) on TNFα-release was similar to the one observed on samples incubated with EXP3174 or losartan alone (Fig. 2A: 63±13% in N+AT+L vs. 33±10% in N+L and 45±10% in N+AT+EXP vs. 41±15% in N+EXP). Under HC, losartan and EXP3174 showed approximately equal efficacies in preventing TNFα release: 1μM losartan or EXP3174 decreased TNFα concentration by 40±15% or 34±20%, respectively (Fig.2 B, H+L vs. H+EXP) when compared to the hypoxic
control (Fig. 2 B, H). Combined application of ATII (100nM) and losartan appeared to decrease TNFα (70±15%, H+AT+L in Fig. 2B) similar to that of ATII with EXP3174 (57±20%, H+AT+EXP in Fig. 2B).

Discussion

Taking into consideration that the AT1-R antagonist losartan is a pharmacologically well characterized therapeutic agent, this study investigated whether this compound and its main active metabolite, EXP3174, may provide a protection of astrocytes against hypoxia-induced cell damage and prevent them from initiating an inflammatory cascade. The data obtained on cell death in terms of LDH release from astroglial cells show that under both NC and HC, losartan and EXP3174 possess a similar protective potency. Astrocytes are known to express all known angiotensin receptor subtypes, namely AT1-R, AT2-R and AT(1-7)-R (30, 31). Their increased survival under losartan and its metabolite may be due to 1) the direct antagonistic effect of losartan and EXP3174 on AT1-R or 2) increased availability of endogenously produced (or exogenously applied) ATII for signal transduction via the remaining receptor subtypes. ATII is known to be produced by astrocytes and to be upregulated under ischemic injury of the brain (11).

Culture condition induces the reactive state of astrocytes, which differs from the resting inactive state typical for these cells in normal brain tissue. This culture-induced activation of astrocytes is entailed by accelerated differentiation and therefore presumably accelerated cell death. It was previously shown that basal release of LDH under normoxic conditions in astroglial cultures is in a range up to 10% of its total intracellular content (32). Results presented here show up to 2.8% LDH release by astroglia under normoxic conditions. Even such a low basal amount of LDH under normoxic conditions in cell culture supernatant was significantly reduced by losartan and EXP3174. Cell culture condition used in this study is the mostly used method over last 20 years for cultivation of astroglial cells. The fact that both compounds (losartan and EXP3174) can increase the viability of cells under well established normoxic culture conditions hint at the possible use of AT1-R blockade as a cell culture supplement capable of creating more physiologic conditions for astroglial cells in vitro. Hypoxia resulted in 30% increase of LDH release. The improvement of astroglial survival under hypoxia after application of losartan or EXP3174 shown here is reconcilable with data demonstrating AT1-R-mediated cell death in myocytes, endothelial cells and blood vessels, in vitro as well as in vivo (33, 34, 35). In contrast to normoxic condition the higher amount of losartan and EXP3174 was needed under hypoxic conditions to improve the survival of astroglial cells: administration of 100nM losartan or EXP3174 revealed no effect on cell survival upon hypoxia. Apparently, AT1-R blockade exerts a direct protective effect on astrocytes during hypoxic injury. Since application of ATII together with EXP3174 was not more efficient in protecting astrocytes from hypoxic cell death than EXP3174 alone, the blockade of AT1-R appears to be more important for survival than the stimulation of AT2-R or A(1-7)-R.

Whether astrocytes can contribute to the local increase of inflammatory factors in response to hypoxia was investigated by multiplex analysis of anti-inflammatory IL-4, IL-5 and GM-CSF, as well as pro-inflammatory IFNγ and TNFα. All these factors have been shown previously to be up-regulated after ischemic injury of the brain (36, 37, 38). IL-4, IL-5, GM-CSF, IFNγ were not detectable under NC or HC. It was previously shown that the exogenous application of IFNγ induces the death of astrocytes via activation of the Jak2/Stat1 pathway in vitro (39). The results...
presented here show that even under protracted HC (48h), astrocytes do not respond with measurable changes in their production of IFN\(\gamma\). The fact that IL-4 release from astrocytes was not influenced by hypoxia is in concordance with the data reported by Park et al. (40) showing that after lipopolysaccharide-induced inflammation of the brain, IL-4 was expressed exclusively in microglia, but not in astrocytes or neurons. Vitcovic et al. (41) have shown that the expression of GM-CSF in astrocytes was not substantially altered by IL-1, an important activator of reactive astrocytosis that is upregulated in astrocytes after hypoxic injury (42). The level of IL-5, an anti-inflammatory cytokine serving as a mitogenic factor for microglia (43) but not for astrocytes (44), was not increased under HC either. The absence of anti-inflammatory IL-4 and 5, as well as pro-inflammatory IFN\(\gamma\) in cell culture supernatants after 48h of hypoxia might hint at a marginal role of these cytokines in the immediate inflammatory response of astrocytes to hypoxia. This suggestion is in agreement with data showing a slight transient increase of IL-4 and IL-5 in microglia and inflammatory leucocytes but not astrocytes during experimental allergic encephalomyelitis (45).

The measured increase in the concentration of TNF\(\alpha\) in the cell culture supernatants under HC suggests that the immediate inflammatory response of astrocytes to hypoxia might be reflected by release of this potent pro-inflammatory cytokine. The application of losartan and EXP3174 decreased the amount of released TNF\(\alpha\) under NC and HC. This effect was pronounced by concomitant administration of ATII. Therefore, different AT receptors may be involved in the maintenance of the inflammatory response of astrocytes. Presumably, the production of TNF\(\alpha\) can be diminished by antagonists at AT1-R and/or stimulation of the other AT receptor subtypes.

The results presented here are somewhat analogous to recently reported data showing the peripheral anti-inflammatory action of the AT1-R antagonist, candesartan, during gastric ulceration (20) to be, in part, reflected by a decreased expression of TNF\(\alpha\) in stomach sections of rats under cold-restraint stress.

AT1-R activation stimulates a multitude of signalling pathways including the nuclear factor-kappaB (NF-\(\kappa\)B) pathway. In astrocytes the induction of this signal effector leads to early up-regulation and subsequent release of TNF\(\alpha\). The inhibition of the NF-\(\kappa\)B transduction pathway was shown to reduce the secretion of TNF\(\alpha\) from astrocytes (46). It can be therefore suggested that decrease of TNF\(\alpha\) release from astroglia provided by losartan or EXP3174 originates most likely from their activation-reducing effect on NF-\(\kappa\)B.

A comparison of the anti-inflammatory effects achieved by losartan and EXP3174 reveals nearly equal efficacy of both compounds under NC and HC, suggesting that losartan delivered to the brain might reduce the susceptibility of astrocytes to hypoxic injury and provide an anti-inflammatory effect even without being converted to EXP3174 in the liver.

In summary, it can be concluded that AT1-R blockade could be of therapeutic benefit during neurodegenerative disorders accompanied by inflammation, such as Alzheimer’s disease, Parkinson’s disease, stroke and multiple sclerosis due to its anti-inflammatory and vulnerability-reducing effect on astrocytes.
Aknowledgments

We appreciate the support of Microbionix (Regensburg, Germany) in performing of multiplex analysis. This work was supported by “Dr. Karl-Kuhn Stiftung” (Tuebingen, Germany) and MSD SHARP&DOHME GmbH (Haar, Germany).

References


(35) Diep QN, Li JS, Schiffrin EL (1999) In vivo study of AT(1) and AT(2) angiotensin receptors in apoptosis in rat blood vessels. Hypertension 34: 617–624.


Figure 1. LDH-release from APCs under NC (A) and HC (B). Losartan applied under NC reduced the release of LDH in a concentration-dependent manner in comparison to control culture (Fig.1A: N vs. 100nM L or 1μM L). Both concentrations of EXP3174 (100nM and 1μM, Fig 1 A) and its simultaneous application with 100nM ATII led to a significant LDH-decrease (AT +1μM EXP in Fig.1A). Under HC (Fig.1B) both, losartan and EXP3174 applied in concentration of 100nM brought no changes in released LDH amount. 1μM losartan or EXP3174 and 100nM AT together with EXP3174 significantly reduced hypoxia-induced cytotoxicity (cf. 1μM L, 1μM EXP and AT+1μM EXP with control H in Fig.1B).
Figure 2. TNFα quantification in APCs under NC (A) and HC (B). The quantification of TNFα revealed a 3.5-fold increase in TNFα-concentration in cell cultures exposed to hypoxia (cf. N in Fig.2A with H in Fig.2B). Under NC (Fig. 2A) losartan and EXP3174 decreased the TNFα-release with an equal potency, whereas under HC the effect of EXP3174 on TNFα-release was considered as insignificant due to a high variability of the data within the treated group (Fig.2B H+EXP). Simultaneous application of ATII with EXP3174 or losartan enhanced the significance of TNFα-reducing effect in NC (Fig.2A, N+AT+L and N+AT+EXP) and HC (Fig. 2B, H+AT+L and H+AT+EXP).
Curriculum Vitae

Name: Sumaira Umbreen
Date of Birth: 11 June 1974
Place of Birth: Bahawalnagar, Pakistan
Nationality: Pakistani
Marital status: Married
Permanent Address: Asif Elysium, Shadman colony, Bahawalnagar, Pakistan

Academic career

April 1992 – September 1994 BSc in Chemistry, Botany, and Zoology,
Institution: University of the Punjab, Pakistan

October 1995 – December 1997 MSc Specialized in Organic Chemistry
Thesis: Development of iridescent colours on glass, ceramic and other related materials.
Institution: University of the Punjab, Pakistan

February 1998 – April 2000 M.Phil. in Organic Chemistry
Institution: Quaid-i-Azam University, Pakistan
Thesis: Synthesis and reactions of medicinally important heterocycles.

Since October 2002 Doctoral thesis under the supervision of Prof. Dr. Boris Schmidt at Technical University Darmstadt, Germany

Since October 2002 Scientific co-worker at Department of Chemistry and Biochemistry, TU-Darmstadt

Language proficiencies

English, Urdu, Punjabi, German (bridging level), Arabic (basic understanding)
Eidesstattliche Erklärung

Ich erkläre hiermit an Eides statt, dass ich meine Dissertation selbstständig und nur mit den angegebenen Hilfsmitteln angefertigt und noch keinen Promotionsversuch unternommen habe.

Sumaira Umbreen
Darmstadt, den